Biogen and Neurimmune announce option exercise for the alzheimer’s disease investigational treatment Aducanumab. Neuroummune will receive a one-time payment of $50 million.
Biogen discovers, develops, and delivers worldwide innovative therapies for people living with serious neurological and neurodegenerative diseases. In 2017, Biogen licensed the worldwide rights to aducanumab, its Phase 3 investigational treatment for early Alzheimer’s disease, from Neurimmune Therapeutics.
Today, Biogen has exercised its option to further reduce the previously negotiated royalty rates payable on potential future sales of aducanumab. The company will make a one-time $50 million payment to Neurimmune in exchange for a 5% reduction in the original royalty rates on potential commercial sales of aducanumab, which follows the 15% reduction in royalty rates announced in October 2017. The reduced royalty rates on potential commercial sales of aducanumab will be in the high single digits to low-teens.
“Biogen values our collaboration with Neurimmune, and this step is aligned with our amended agreement from 2017,” said Michel Vounatsos, chief executive officer of Biogen. “As we progress our pipeline of candidates for Alzheimer’s disease including aducanumab, we hope that a potential treatment for this devastating and debilitating disease will be realized.”
“At Neurimmune, we are pleased with the continuous progress of our long-term successful collaboration with Biogen”, said Roger Nitsch, chief executive officer of Neurimmune. “This non-dilutive financing supports our growth strategy focused on bringing human-derived antibodies through clinical proof-of-concept in disease areas with high medical need.”
(Press release/ran)
Please login or sign up to comment.
Commenting guidelines